Inflammatory Bowel Disease and Your Periodontal Health

The Connection Between IBD and Gum Disease

If you have been diagnosed with Crohn's disease, ulcerative colitis, or another form of inflammatory bowel disease (IBD), you may not realize that your condition has a direct connection to the health of your gums. A growing body of research, including multiple large-scale studies and systematic reviews, has established that IBD patients are significantly more likely to develop periodontal disease (gum disease) than the general population.

A 2022 meta-analysis that pooled data from over 1,700 studies found that patients with IBD had 2.65 times higher odds of having periodontitis compared to people without IBD. When the researchers looked at each type of IBD separately, the risk was elevated for both: patients with Crohn's disease were about 2.2 times more likely to have gum disease, while patients with ulcerative colitis were 3.5 times more likely. A more recent 2025 network meta-analysis of over 9,000 patients confirmed these findings, reporting that periodontitis prevalence was significantly higher among both Crohn's and ulcerative colitis patients compared to healthy individuals.

Importantly, a 2024 Mendelian randomization study, which uses genetic data to test for cause-and-effect relationships, found evidence that the relationship goes both ways: Crohn's disease appears to be a risk factor for developing periodontitis, and periodontitis appears to worsen ulcerative colitis. This supports the existence of a true "mouth-gut axis" in which the two diseases influence each other.

Why Does IBD Affect Your Gums?

IBD and periodontal disease share a common underlying problem: a dysregulated immune-inflammatory response. In both conditions, the body's immune system overreacts to bacteria in ways that damage the surrounding tissues. Several specific mechanisms connect the two.

Shared Inflammatory Pathways

Both IBD and periodontitis are driven by excessive production of the same inflammatory molecules, including TNF-α, interleukin-1β, interleukin-6, and other cytokines. When your IBD is active, these molecules circulate at elevated levels throughout your body, not just in your gut. This systemic inflammation can amplify the destructive inflammatory response in your gum tissues, accelerating periodontal attachment loss and bone destruction.

The Oral-Gut Bacterial Axis

Research has shown that oral bacteria, particularly species associated with gum disease such as Porphyromonas gingivalis, can be swallowed and colonize the gut, where they may contribute to intestinal inflammation. At the same time, the altered gut microbiome in IBD patients appears to influence the oral microbiome, creating a feedback loop between the two sites. Studies in treatment-naïve pediatric IBD patients have demonstrated significant changes in oral bacterial communities that correlate with disease severity.

Immune System Dysregulation

IBD fundamentally alters how your immune system responds to bacterial challenge. The same genetic susceptibility factors, including variations in the NOD2 gene (which is strongly associated with Crohn's disease), affect immune function in both the gut and the oral cavity. When your immune system is not functioning normally, the bacteria that cause gum disease can do more damage with less resistance from your body's defenses.

Nutritional Deficiencies

IBD frequently causes malabsorption of nutrients critical to gum health, including vitamin D, calcium, iron, and B vitamins. These deficiencies can impair your gum tissue's ability to heal and maintain itself, making you more susceptible to periodontal breakdown.

How IBD Medications Affect Your Periodontal Treatment

The medications used to manage IBD have important implications for your periodontal care. Dr. Yant needs to know exactly which medications you are taking so that your treatment can be planned safely:

Corticosteroids (prednisone, budesonide)

Long-term corticosteroid use suppresses the immune system broadly, which can slow wound healing after periodontal procedures and increase susceptibility to oral infections. Additionally, chronic corticosteroid use increases the risk of osteoporosis, which can contribute to alveolar bone loss, the very bone that supports your teeth. If you are on prednisone or similar medications, Dr. Yant may take additional steps to support healing after surgery.

Immunosuppressants (azathioprine, methotrexate, 6-mercaptopurine)

These drugs reduce the activity of your immune system to control IBD inflammation. While they are effective for your bowel disease, they also reduce your body's ability to fight oral infections and can slow healing after periodontal surgery. Dr. Yant will coordinate with your gastroenterologist to ensure the timing of any surgical procedures minimizes risk. Importantly, current evidence suggests that routine periodontal procedures do not require stopping these medications. The interruption provides no benefit and risks disease flare.

Biologic Therapies (infliximab/Remicade, adalimumab/Humira, vedolizumab/Entyvio, ustekinumab/Stelara)

Biologics target specific components of the inflammatory cascade. Anti-TNF-α drugs like infliximab and adalimumab have actually been shown in some studies to improve periodontal measures, reducing alveolar bone loss and improving gum attachment, because they suppress the same inflammatory molecules that drive both IBD and periodontal destruction. However, biologics also carry a risk of impaired wound healing and increased infection susceptibility. For elective periodontal surgery, Dr. Yant may schedule your procedure at the end of a dosing interval, when the immunosuppressive effect is at its lowest, and will coordinate with your prescribing physician.

Key Point for Your Treatment

Never stop or change the dose of your IBD medications without consulting both your gastroenterologist and Dr. Yant. Stopping immunosuppressive therapy risks a disease flare, which can be more dangerous than the theoretical infection risk of continuing the medication through a dental procedure. The decision to adjust medications around periodontal surgery should always be made collaboratively between your medical and dental teams.

What This Means for Your Periodontal Care

If you have IBD, your periodontal care requires some important adaptations:

• More frequent monitoring. Because IBD increases your risk for periodontal disease progression, Dr. Yant may recommend more frequent maintenance visits, typically every 3 months rather than every 6 months, to catch and address any changes early.

• Coordination with your GI team. Dr. Yant and your gastroenterologist should communicate about your disease activity, medication regimen, and any planned procedures. This is especially important if you are on biologics or high-dose corticosteroids.

• Attention to disease flares. During active IBD flares, your immune system is under significant stress, and systemic inflammation is elevated. Elective periodontal procedures are best scheduled during periods of disease remission when possible, as healing is more predictable and the risk of complications is lower.

• Nutritional support. If malabsorption is a concern, your medical team may recommend supplementation of key nutrients (vitamin D, calcium, B vitamins) that support both gut and gum health.

• Oral manifestations of IBD. Crohn's disease in particular can produce oral lesions including cobblestoning of the oral mucosa, deep linear ulcers, lip swelling, and angular cheilitis. If you notice any unusual changes in your mouth, let both Dr. Yant and gastroenterologist know, as these may reflect changes in your disease activity.

The Positive Takeaway

Managing your IBD effectively is one of the best things you can do for your gums. When your bowel disease is well-controlled and systemic inflammation is reduced, your periodontal health benefits directly. Likewise, treating and controlling gum disease reduces the inflammatory burden on your whole body, which may support better IBD outcomes. Taking care of one condition helps the other.

Sources

This article is based on peer-reviewed research published in leading medical and dental journals.

• Bertl, K., et al. (2023). Health-related quality of life in the "Periodontitis Prevalence in Ulcerative Colitis and Crohn's Disease" (PPCC) cohort. Journal of Clinical Periodontology, 50(12), 1601–1620.
• Elmaghrawy, K., et al. (2023). The oral microbiome in treatment-naïve paediatric IBD patients exhibits dysbiosis related to disease severity. Journal of Crohn's and Colitis, 17(4), 553–564.
• Farahani, A., et al. (2025). A systematic review and network meta-analysis of the association between periodontitis and inflammatory bowel diseases. BMC Oral Health, 25, 412.
• Huang, X., et al. (2024). Linking periodontitis with inflammatory bowel disease through the oral-gut axis. Biomedicines, 12(3), 685.
• Lira, R., & Figueredo, C. M. (2016). Periodontal and inflammatory bowel diseases: is there evidence of complex pathogenic interactions? World Journal of Gastroenterology, 22(35), 7963–7972.
• Qing, X., et al. (2024). Causal association analysis of periodontitis and inflammatory bowel disease: a bidirectional Mendelian randomization study. Inflammatory Bowel Diseases, 30(8), 1251–1257.
• She, Y. Y., et al. (2020). Periodontitis and inflammatory bowel disease: a meta-analysis. BMC Oral Health, 20(1), 67.
• Tzellos, T., et al. (2022). Patients with inflammatory bowel disease have a higher chance of developing periodontitis: a systematic review and meta-analysis. Frontiers in Medicine, 9, 1020126.
• Zhou, T., et al. (2023). The effect of the oral-gut axis on periodontitis in inflammatory bowel disease: a review. Frontiers in Cellular and Infection Microbiology, 13, 1132420.